BlueDot
BlueDot is a Toronto-based AI and human-expert infectious disease intelligence company serving public health agencies, pharma/life sciences, and global enterprises with always-on global surveillance, predictive outbreak risk assessments, and API-accessible disease intelligence.
- Company typePrivate
- Founded2013
- HeadquartersToronto, Canada
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What BlueDot does
BlueDot is a Toronto-headquartered, venture-backed company founded in 2013 by Dr. Kamran Khan that builds AI-powered infectious disease intelligence for governments, life sciences organizations, and global enterprises. Its core platform combines always-on automated surveillance (monitoring 190+ diseases and syndromes across 130+ languages via NLP on roughly 11 million online articles per month, integrated with global air-travel data from 4+ billion ticket sales per year) with human expert analysis from in-house epidemiologists and clinicians. The product surface includes the BlueDot Insights Platform, Event Alerts, Intelligence Reports, Horizon Scanning and Risk Assessments, Predictive Intelligence, the Risk Analysis Toolkit, Wastewater Intelligence, Avian Influenza Pulse Reports, and the BlueDot Assistant and Personalized Briefs products (LLM-powered interfaces using Cohere and OpenAI technology).
The company's commercial offer is delivered primarily as annual subscription access to the BlueDot Insights platform, with API/data licensing for embedding intelligence into enterprise systems and additional distribution through a Microsoft AppSource listing and a Clarivate channel partnership that reaches life sciences buyers. Customers span public health agencies (NATO, Taiwan CDC, City of Chicago, ASEAN, Japan NIID, NCGM Japan), pharmaceuticals and life sciences, and global enterprises (Air Canada, Reckitt, Meiji, GTAA). Headcount sits in the 51-100 range, total disclosed funding is approximately $12.5M USD across rounds from 2013 through a January 2023 Government of Canada grant, and the company has earned recognition including the Financial Times Americas' Fastest Growing Companies 2024 ranking, a Globe and Mail Canada's Top Growing Companies No. 25 placement, Deloitte Technology Fast 50 No. 15, and Newsweek's World's Best Digital Health Companies 2024 list.
BlueDot firmographics
Firmographics- Name
- BlueDot
- Legal name
- BlueDot Inc.
- Website
- https://bluedot.global
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BlueDot is a Toronto-based AI and human-expert infectious disease intelligence company serving public health agencies, pharma/life sciences, and global enterprises with always-on global surveillance, predictive outbreak risk assessments, and API-accessible disease intelligence.
- Ownership category
- akta.pro rank
BlueDot industry classification
Industry- Product category
- Infectious Disease Intelligence
- NAICS
- Web Search Portals and All Other Information Services (519290)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Digital Epidemiology & Event-Based Surveillance (media/mobility) (HLAJABAJ)
- akta.pro secondary industries
- Disease & Condition Surveillance Programs (HLAJANAB), Population Health Surveillance & Epidemiologic Analytics (HLAJAJAB)
Keywords
Where BlueDot is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
BlueDot business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Disease Intelligence Subscriptions: BlueDot provides disease-alert subscriptions to governments, airlines, pharmaceutical companies, and enterprises. Subscriptions to the BlueDot Insights platform provide outbreak alerts, structured data assets, forecasting models, and expert-written risk assessments. Subscription is required to use products and services.
- Data Licensing and API Access: BlueDot provides API access for direct integration of their intelligence into existing client workflows, allowing enterprise customers to embed disease intelligence into their own systems and surveillance platforms.
- Partnership Distribution: Through partnerships with Clarivate and Microsoft, BlueDot's intelligence is distributed to customers of these platforms, creating additional revenue streams through channel distribution.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Subscription-based access to disease intelligence platform |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
BlueDot product offering
Product offeringCore offering
BlueDot provides an AI-powered infectious disease intelligence platform that monitors over 190 diseases and syndromes globally by combining natural language processing, machine learning, and large language models with expert human analysis from epidemiologists and clinicians. The platform delivers near real-time alerts, risk assessments, forecasting models, and curated intelligence reports to governments, pharmaceutical companies, and global enterprises for early outbreak detection and response.
Product overview
BlueDot offers a unified infectious disease intelligence platform called BlueDot Insights, which combines AI-powered automated surveillance with expert human analysis. The core platform monitors over 190 infectious diseases and syndromes in 130 languages through continuous scanning of global data sources. The platform's main products include: BlueDot Insights (core platform), BlueDot Assistant (LLM-powered natural language interface using Cohere and OpenAI), Personalized Briefs (automated location-based reporting), Event Alerts (rapid expert risk assessments), Intelligence Reports (comprehensive expert analysis), and specialized offerings including Wastewater Intelligence (early warning via wastewater surveillance), Avian Influenza Pulse Reports (weekly expert briefings), Mpox Response (clade-specific tracking), Risk Analysis Toolkit, Horizon Scanning, Predictive Intelligence, and a BlueDot API for workflow integration. The platform serves three main sectors: Public Health (government health agencies), Pharma & Life Sciences (vaccine and therapeutic organizations), and Global Enterprise (businesses protecting operations and workforce). BlueDot was founded in 2013 and is headquartered in Toronto, Canada.
Differentiator
Problem solved
Functional benefit
Products and services
- BlueDot Insights Platform Cloud-based infectious disease intelligence platform that combines human expertise with AI to track, contextualize, and anticipate risks from hundreds of infectious diseases worldwide for public health agencies, pharmaceutical companies, and global enterprises.
- BlueDot Assistant LLM-powered natural language interface that enables users to query BlueDot's global health and novel datasets through conversational prompts, generating pre-made tables, downloadable CSV files, and reducing manual detection time by nearly 90%.
- Personalized Briefs Automated daily or weekly snapshots of disease activity tailored to user-defined locations, featuring pre-cleansed case statistics, rapid risk assessments, emerging ILI trends, travel data, and expert commentary.
- Wastewater Intelligence Wastewater surveillance intelligence capability providing early warning of emerging ILI trends and outbreaks in the United States at state-level, available approximately one week ahead of CDC's NWSS, with pre-transformed actionable metrics.
- Avian Influenza Pulse Reports Weekly expert-written reports providing overviews of emerging and ongoing avian influenza activity across humans and animals globally, including week-over-week trends, rapid risk assessments, and research updates.
- Mpox Response Enhanced surveillance solution for mpox with clade-specific tracking of Clade I and Clade II activity separately, including case trends, live news streams, rapid risk assessments, and expert-contextualized outbreak updates.
- BlueDot API API providing direct programmatic access to BlueDot's infectious disease intelligence, alerts, risk assessments, and surveillance data for integration into existing client workflows and enterprise systems.
Quantifiable outcome
- Alerted clients of COVID-19 threat 5 days before WHO
- +6 more outcomes
Companies that use BlueDot
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
BlueDot technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability7 records
Feature7 records
BlueDot partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- MicrosoftcoreBlueDot became a Microsoft Partner providing enterprise organizations with AI-powered infectious disease intelligence. Solution is available on Microsoft AppSource for direct customer access.
- Health MatrixminorHealth Matrix expanded its public health portfolio in the Middle East by partnering with BlueDot to provide disease intelligence solutions to clients in the region.
- NCGM (National Center for Global Health and Medicine, Japan)coreBlueDot signed agreement with NCGM of Japan to strengthen Japan's readiness and resilience to infectious disease outbreaks. NCGM leverages BlueDot's global intelligence and subject-matter expertise for earlier threat identification, bolstering horizon scanning, and increasing depth/timeliness of risk assessments.
- ClarivatecorePartnership announced November 2022 enables Clarivate customers to access BlueDot's AI and machine learning-based infectious disease intelligence. Spans emerging and seasonal diseases with alerts, risk assessments, datasets, and analysis. Empowers life sciences customers with unparalleled analysis and customer-focused alerts.
- GTAA (Greater Toronto Airport Authority)coreGTAA partnered with BlueDot to power their Healthy Airport commitment, a comprehensive program for preparing for new realities of air travel. BlueDot provides advanced data analytics to enable smarter, safer travel experiences.
- ParticleOneminorBlueDot and ParticleOne partnership helps businesses and governments protect people and mitigate disruption through combined disease intelligence capabilities.
- HuronminorBlueDot, Inc. and Huron joined forces to strengthen organizations' response to epidemics through consulting and implementation partnership.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
BlueDot competitors and assessment
Company assessmentDirect peers
- Airfinity: London-based infectious disease intelligence platform serving pharma and life sciences with outbreak forecasts, vaccine/demand modeling, and epidemiological analytics — the closest pure-play competitor to BlueDot on the pharma-facing side.
- HealthMap: Boston Children's Hospital-hosted automated real-time disease outbreak monitoring system using multilingual news, official alerts, and other signals — comparable to BlueDot's event-based surveillance engine.
- Metabiota (Booz Allen Hamilton): Originally an independent epidemic risk analytics firm (acquired by Booz Allen in 2022), offering pandemic risk modeling and surveillance intelligence for governments and insurers — directly competitive on outbreak risk analytics.
Emerging players
- Ginkgo Bioworks (Biosecurity): Through its biosecurity unit, Ginkgo operates large-scale pathogen monitoring and biological threat detection infrastructure, overlapping with BlueDot's surveillance capabilities on a broader US federally-funded footprint.
- Biobot Analytics: Wastewater-based epidemiological intelligence company providing early warning of disease outbreaks (including ILI trends) at municipal level — directly comparable to BlueDot's Wastewater Intelligence module.
- Sickweather: Real-time illness tracking platform using social media and search data to forecast outbreaks — narrower consumer-focused scope but comparable crowdsourced/event-based surveillance methodology.
- Descartes Labs: AI/data platform that has applied geospatial and predictive analytics to public-health and biosecurity use cases — comparable on the AI-for-epidemiology axis though not a direct disease-surveillance competitor.
Broad incumbents
- Palantir Technologies: Through its Foundry platform, Palantir has deployed public-health and biosurveillance solutions for governments (e.g., US HHS, UK NHS), representing a broader incumbent with overlapping capabilities and far greater scale.
- Microsoft: Both a distribution partner (AppSource) and potential substitute via Microsoft AI for Health and Azure-based health-security offerings — overlap is broad and indirect but increasingly competitive as Microsoft bundles disease intelligence into enterprise contracts.
Others
- Clarivate: Partner and distributor of BlueDot's intelligence into life-sciences customers; also operates its own epidemiology and biopharma intelligence products that overlap with BlueDot's pharma value proposition.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
BlueDot social profiles
Digital presenceBlueDot compliance and trust
Trust signalCompliance3 records
BlueDot financial estimates
Financial estimateRevenue estimate
Valuation estimate
BlueDot leadership team
Management profileNumber of profiles
Profiles6 records
BlueDot funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BlueDot M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BlueDot
What does BlueDot do?
BlueDot provides an AI-powered infectious disease intelligence platform that monitors over 190 diseases and syndromes globally by combining natural language processing, machine learning, and large language models with expert human analysis from epidemiologists and clinicians. The platform delivers near real-time alerts, risk assessments, forecasting models, and curated intelligence reports to governments, pharmaceutical companies, and global enterprises for early outbreak detection and response.
Is BlueDot a public or private company?
BlueDot is a private company. It is classified as venture growth investor backed and is currently operating.
When was BlueDot founded?
BlueDot was founded in 2013. It employs 51 to 100 people.
Where is BlueDot based?
BlueDot is headquartered in Toronto, Canada, in the North America region.
How does BlueDot make money?
Three revenue lines are on record. Disease Intelligence Subscriptions are the primary driver. The others are data Licensing and API Access and partnership Distribution.
Who are BlueDot's main competitors?
Direct peers on record are Airfinity, HealthMap and Metabiota (Booz Allen Hamilton). Emerging players are Ginkgo Bioworks (Biosecurity), Biobot Analytics, Sickweather and Descartes Labs. Broad incumbents are Palantir Technologies and Microsoft. Clarivate is listed as an others.
Does BlueDot have an API?
Yes. BlueDot provides API access for direct integration of their intelligence into existing workflows. The API allows developers to embed BlueDot's infectious disease intelligence, including alerts, risk assessments, and surveillance data, into third-party applications and business systems. Developer documentation is at portal.bluedot.global.
What industry is BlueDot in?
BlueDot's product category is Infectious Disease Intelligence. Its primary akta.pro industry code is HLAJABAJ, Digital Epidemiology & Event-Based Surveillance (media/mobility), with a secondary code of HLAJANAB, Disease & Condition Surveillance Programs. Its NAICS code is 519290 and its SIC code is 8000.